Count what it takes to keep one weekly injection going. There is the insurance premium, which pays for a primary care physician who has your history and your past labs and who will not write the prescription. There is the membership app that does write it. And there is the telehealth service you turn to for a signature when you need one quickly. If your PCP won't prescribe GLP-1 medication and you have pieced this arrangement together to get treated anyway, you are paying three parties, and none of them is responsible for the whole of your care.
So the question you came with is a fair one: why would you pay for a membership when you just want the prescription? This piece answers it for that situation and no other. The person described here is a composite, not a real patient. The short answer is that you already pay for access three times over. What none of those payments buys is one clinician who sees your labs, writes the prescription and adjusts it over time. Whether that is worth $299 a month is your call, and the last section says plainly when it is not. If you would rather start with the practical question of whether you would be accepted, the eligibility check is the first step.
- A GLP-1 prescription is the output of a clinician's ongoing judgment, and the judgment is what you pay for.
- In a three-party setup, the clinician with your labs and the clinician with your prescription are different people.
- GoodLife Health is $299 a month, month to month, with four cardiometabolic lab panels a year included.
- Medication goes to the pharmacy you choose, at that pharmacy's price, and GoodLife Health takes nothing on it.
- The membership pairs with insurance for catastrophic coverage and does not replace it.
- Not everyone is accepted, and no prescription is promised; the clinician decides.
Three bills, three portals, and nobody holding the whole chart
Start with what each party actually does for you, because each one does something.
Your primary care physician has the longest view. Your insurance pays for the visits, the office holds your history, and when labs are drawn, the results go there. But the answer on the medication was no. With traditional primary care appointments averaging 18 minutes, a no can easily be where the conversation ends. So the physician who knows you best has stepped out of the one decision you most wanted help with.
The app fills that gap. It writes the GLP-1 prescription, and for a while that felt like the problem solved. What it may not have is the rest of you: the lab work your physician ordered, the other medications your physician manages, the reason a dose left you feeling unwell in the second month. It knows what you told it at intake and whatever you have remembered to update since.
The telehealth signer is the thinnest relationship of the three. You use it to produce a signature when the app is slow or a refill falls through, and once the signature exists, the relationship is over. That is the job it does, and it does that job. It was never set up to know you.
Now look at what happens in the gaps. You have nausea in the third week of a new dose: which of the three do you message? A routine lab from your physician shows a number has moved: does anyone tell the app? The app raises your dose: does your physician's chart reflect it? Your medication list exists in three versions, each slightly out of date. When something needs a judgment, the question of who owns it gets settled by whoever you happen to reach first.
None of this means anyone is being careless. Each party is doing the narrow job you hired it for. The trouble is in the structure: you hired three narrow jobs, and the job that runs across all three, connecting your labs to your dose and your dose to how you feel, was never assigned to anyone. You have been doing it yourself, by forwarding screenshots and repeating your history to each new person.
And you pay for all three: the premium, the app's fee, whatever the signer charges, and then the medicine on top, priced by whoever fills it. Each charge buys a slice, and no charge buys the whole.
What you are really buying when you buy a prescription
The objection rests on a reasonable idea: the prescription is the product, and everything around it is overhead. For a GLP-1, that idea does not hold up for long.
A GLP-1 prescription is the visible end of a series of decisions. Should you start at all, given your history and your labs? Which medication, and in which form? At what dose, and when should it step up? When should a dose be held because the side effects are telling you something? What does the next set of labs say about whether the plan is working? Those decisions are made over months, and each one is only as good as the information behind it. As our guide to what direct primary care includes explains, metabolic labs (fasting glucose, HbA1c, a lipid panel and liver enzymes) are standard before GLP-1 therapy begins, because a protocol built without them is a guess.
In your current setup, the information and the decision live in different places. The labs sit with the physician who will not prescribe. The prescription sits with an app that may never have seen them. That split is the real cost of the arrangement, and it appears on none of the three bills.
There is also the question of how each party is paid, which our plain-language white paper on how GLP-1 telehealth companies make money works through in detail. Every company that prescribes these medicines earns its money in one of three ways: a margin on the medicine, a low membership fee plus billing your insurance, or one flat fee with the medicine sold at the pharmacy's own price. As the paper puts it, the way a company gets paid is the pressure its clinicians work under. That does not make anyone good or bad; it decides what the company is rewarded for.
That gives you a practical test for the app you already use. Find the price of the medicine itself on its pricing page, then compare it with the manufacturer's own self-pay price. The comparison chart behind the white paper, compiled from public pricing pages in May 2026, found branded Zepbound or Mounjaro offered at up to $1,899 a month through legacy telehealth memberships. Through LillyDirect, Zepbound vials were $299 to $449 a month depending on dose, as published in September 2026. If your app's medicine price sits above the manufacturer's, the difference is the company's margin. That is the model in which the membership fee looks small and the medicine carries the profit.
One more check is worth doing. If what your app sends is a compounded copy rather than a branded medicine, the rules changed in 2025. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and the last enforcement grace periods closed that spring. A narrow exception remains for a pharmacy compounding for one specific patient with a documented clinical need. The FDA sets out its concerns about unapproved GLP-1 drugs, and the white paper gives the full timeline. A clinician's license carries the responsibility for what is prescribed, which is one more reason to know exactly who that clinician is.
Put plainly, you already pay for access three times over; what none of the three sells you is one clinician who sees your labs and answers for the dose.
You already pay for access three times over; what none of the three sells you is one clinician who sees your labs and answers for the dose.
One care team instead of three, and what it costs
GoodLife Health is a clinician-led practice built on the direct primary care model: precision direct primary care for Cardiometabolic Optimization. The order matters. Diagnosis comes first, then treatment, then the long haul. For someone in your position, the change is that the labs, the prescription and the adjustments all sit with the same care team.
The membership covers clinicians licensed in all fifty states; four cardiometabolic lab panels a year, so labs every quarter, with every result in your hands; asynchronous messaging with the care team, so the week-three nausea question goes to the people who set the dose; and video visits. The fee is the same whatever medication is indicated and whatever the dose, with no molecule upcharge and no dose upcharge.
Medication is unbundled, and this is the part that most directly answers your objection. When a clinician judges a medication clinically indicated, it is prescribed to the pharmacy you choose, at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on medication, so the practice earns the same whatever the clinician decides. What is prescribed is branded and FDA-approved: Wegovy, Zepbound, Mounjaro or Ozempic for GLP-1 therapy, and any other FDA-approved medication a clinician judges indicated. No compounded GLP-1 is prescribed, ever, which means you pay the branded price, and that price is higher. The manufacturers now publish their own self-pay prices. As published in September 2026, NovoCare listed Wegovy pens at $199 a month for the first two fills (an introductory offer for new patients through December 2026) and $349 a month after, and the Wegovy pill from $149 a month at lower doses. LillyDirect listed Zepbound vials at $299 to $449 a month depending on dose.
The membership is $299 a month, month to month, which is $3,588 a year. At sign-up, $598 is charged to cover the first two months. If the clinician cannot accept you into care, the $598 is refunded in full; once you are accepted, the first two months are non-refundable. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. The membership fee is generally eligible for HSA or FSA pre-tax dollars.
Who handles what
| Question | Your current setup | One GoodLife Health membership |
|---|---|---|
| Who writes the GLP-1 prescription | The app, or the signer when needed | A GoodLife Health clinician, when clinically indicated |
| Who orders and reads your labs | Your PCP, who will not prescribe | The same care team, four panels a year |
| Who adjusts the dose | Whichever of the three you reach | The clinician who has your labs |
| Who sets the medicine price | Whoever fills the prescription | The pharmacy you choose, at its own price |
| Where your questions go | Three separate places | One care team, by message or video |
A GLP-1 dose is a decision made over months, against labs. Baseline metabolic labs come before therapy starts, and the same clinicians reading the follow-up panels is what lets a dose be adjusted on evidence.
Now, what the membership does not do. It does not replace your insurance. The membership pairs with insurance for catastrophic coverage, such as hospital stays and emergencies, which a primary care relationship was never going to cover. What it replaces is the primary-care relationship. That is a real decision about your current physician, and it deserves some thought.
It does not promise a prescription. Not everyone is accepted, and the path runs in a fixed order: the eligibility check, the intake, the checkout, then a clinician's review. If a GLP-1 is not indicated for you, the clinician will say so, and that answer is part of what the fee pays for.
It does not run your prior authorization. If you hope insurance will cover the medication, that is between you, your plan and the pharmacy, and prior authorization is the pharmacy's process. GoodLife Health does not claim to speed it or win it, and coverage is never promised. Nor does the membership promise any particular result: there is no guaranteed or typical weight loss.
So, is a membership worth it when you only want the prescription?
The honest answer has two halves.
If what you want is the signature alone, the quickest route to a pen in your hands, then this membership is the wrong purchase, and you should not let anyone talk you into it. GoodLife Health sits between the $20,000-a-year concierge practice and the $99-a-month compounded app, and says so. It costs more than most memberships and does not try to win on price at the low end.
If what you want is the prescription plus someone who answers for it, then you are already paying for that in three installments and receiving it in pieces. The membership asks you to pay once for the whole. It may mean the app and the signer are no longer needed, but that depends on what a clinician decides after reviewing you, which is why none of it is promised in advance.
The way to decide is to do your own arithmetic with your own numbers. Write down what you pay now in a year: the premium, the app's fees, the signer's charges and the medication at the price you pay. Then write down the alternative: the premium, which you keep either way for catastrophic coverage; $3,588 for the membership; and the medication at your chosen pharmacy's price, using the manufacturer's published self-pay figures if you buy direct. Date every price you use, because these prices move. If the second column costs more, you are deciding whether one accountable care team and quarterly labs are worth the difference to you. If it costs less, the decision is easier, and you should still read the next section before you make it.
Who this is not for
If you want the lowest monthly price for a GLP-1 and nothing else, this is not for you. That includes the $99 buyer, and saying so plainly is deliberate. If you want a compounded GLP-1, it is not for you, because none is prescribed here. If you want a guarantee that you will leave with a prescription, or that your insurance will pay for the medication, it is not for you, because neither can be promised honestly. If you are hoping to drop your insurance, it is not for you either; the membership is built to sit alongside it. And if your current physician is a relationship you value for everything else in your health, and you would rather solve the GLP-1 question some other way than replace that relationship, that is a reasonable choice. A membership should not be the reason you give it up.
If you have read this far and the fragmentation still sounds like the thing you most want fixed, the next step is small: check whether you are eligible, and let a clinician decide whether you are a fit.
Related Reading
- How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
- What Does Direct Primary Care Include in 2026
References
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss